Cosmos Health Inc (COSM)

$0.65 +0.01 (1.90%)
Market Cap 19.61M
Revenue (ttm) 54.43M
Net Income (ttm) -16.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -29.73%
Debt to Equity Ratio 0.39
Volume 244,000
Avg Vol 749,514
Day's Range N/A - N/A
Shares Out 30.21M
Stochastic %K 17%
Beta 5.31
Analysts Strong Buy
Price Target $3.00

Company Profile

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It also provides ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvas...

Industry: Medical Distribution
Sector: Healthcare
Phone: 312 536 3102
Address:
141 West Jackson Boulevard, Suite 4236, Chicago, United States
Luvmepup
Luvmepup Sep. 7 at 1:07 PM
$COSM Investors before Sept 29
0 · Reply
Luvmepup
Luvmepup Sep. 7 at 1:05 PM
$COSM Don't forget baggies, this has to be at or above $1 for ten straight business days BEFORE Nov. My prediction ... as soon as this crooked CEO gets the approval for a Reverse Split Sept 29, BOOM!
0 · Reply
Luvmepup
Luvmepup Sep. 7 at 12:30 PM
$COSM Just to be clear ... this scam will continue to get hammered this week!
0 · Reply
Kid_Shelleen
Kid_Shelleen Sep. 7 at 11:19 AM
$COSM COSM
0 · Reply
lightstorm
lightstorm Sep. 7 at 5:52 AM
$COSM Just to be clear, COSM has about 32M shares outstanding right now. The 1.5B number in the proxy refers only to authorized shares, which is the legal ceiling the company could issue in the future. That doesn’t mean they issue those shares and the float suddenly jumps to 1.5B . Issuing new shares would require separate offerings and board decisions, it’s not automatic. Outstanding shares remain what they are unless new shares are actually issued. This is a standard step for small caps to keep financing options open, not an automatic dilution event.
0 · Reply
lightstorm
lightstorm Sep. 7 at 5:32 AM
$COSM Worth keeping in mind — filing a proxy for reverse split authority is standard Nasdaq procedure whenever a stock is under $1 near a deadline. It doesn’t mean a split is automatic. In 2024, COSM regained compliance organically without touching the split authority because they pushed strong PRs and growth news. Greg still holds millions of shares himself, so his interests are aligned with ours. The 14A just gives the board a fallback option if all else fails — nothing unusual about that. What matters now is whether management executes the same playbook (PR cadence + catalysts) to get us back over $1 before November.
0 · Reply
WallStVisions
WallStVisions Sep. 7 at 1:01 AM
SKYQ is building something big: → Tokenizing energy assets → Expanding clean-tech operations → Bottomed chart, tiny cap → Major upside if volume steps in This one can go from sleeper to spotlight real quick… $MBOT $PEV $COSM $LEXX
0 · Reply
Luvmepup
Luvmepup Sep. 6 at 8:42 PM
$COSM You baggies do realize you are about to lose your asses this week? What made you think holding longer would cause pigs to start flying? This week will be a complete shit-show ... DO NOT DOUBT ME! This crooked CEO is hemorrhaging cash like nobody's business ... hence the new Offering. He also knows he will never be able to get back to $1 ... hence the Reverse Split that no doubt is coming right after the proxy vote in three weeks.
0 · Reply
Luvmepup
Luvmepup Sep. 6 at 6:56 PM
$COSM To think, poster BearTrapper used to deny what I was telling him and this board for years about how corrupt this company/CEO was/is. Now he realizes what a "dirty scam" this company is. Still no apology though.
0 · Reply
WallStVisions
WallStVisions Sep. 6 at 5:58 PM
SKYQ isn’t just undervalued it’s misunderstood. This is a blockchain + energy sleeper play with real revenue, a real platform, and no dilution. It’s not a matter of if this explodes it’s when. $1+ is right there…. $PEV $SNTI $COSM $VERB
0 · Reply
Latest News on COSM
Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025

Aug 18, 2025, 12:45 PM EDT - 19 days ago

Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025

Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy

Aug 12, 2025, 9:50 AM EDT - 26 days ago

Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy

Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy

Aug 6, 2025, 9:20 AM EDT - 4 weeks ago

Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

Jun 24, 2025, 10:55 AM EDT - 2 months ago

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

May 15, 2025, 2:30 PM EDT - 4 months ago

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

May 15, 2025, 9:30 AM EDT - 4 months ago

Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

May 7, 2025, 2:30 PM EDT - 4 months ago

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

May 6, 2025, 1:40 PM EDT - 4 months ago

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Apr 30, 2025, 12:50 PM EDT - 4 months ago

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Apr 16, 2025, 12:45 PM EDT - 5 months ago

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

Apr 9, 2025, 1:40 PM EDT - 5 months ago

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

Apr 8, 2025, 10:45 AM EDT - 5 months ago

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates

Feb 26, 2025, 11:30 AM EST - 6 months ago

Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates

Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1

Feb 18, 2025, 8:30 AM EST - 7 months ago

Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1

Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market

Feb 11, 2025, 10:15 AM EST - 7 months ago

Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market

Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

Feb 10, 2025, 1:30 PM EST - 7 months ago

Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations

Feb 10, 2025, 9:45 AM EST - 7 months ago

Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations

Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility

Feb 7, 2025, 10:00 AM EST - 7 months ago

Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility

Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar

Feb 6, 2025, 3:50 PM EST - 7 months ago

Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar

Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market

Feb 5, 2025, 11:05 AM EST - 7 months ago

Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market

Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow

Jan 28, 2025, 11:00 AM EST - 7 months ago

Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow

Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion

Jan 27, 2025, 3:50 PM EST - 7 months ago

Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

Jan 23, 2025, 3:35 PM EST - 8 months ago

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

VRAX

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

Jan 22, 2025, 8:00 AM EST - 8 months ago

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Jan 21, 2025, 3:00 PM EST - 8 months ago

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Jan 13, 2025, 9:20 AM EST - 8 months ago

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

VRAX

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Dec 26, 2024, 1:30 PM EST - 9 months ago

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

Dec 23, 2024, 9:25 AM EST - 9 months ago

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

Nov 18, 2024, 8:00 AM EST - 10 months ago

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M

Nov 15, 2024, 10:20 AM EST - 10 months ago

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M

Cosmos Health Issues Letter to Shareholders

Nov 12, 2024, 12:00 PM EST - 10 months ago

Cosmos Health Issues Letter to Shareholders

Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%

Nov 1, 2024, 12:30 PM EDT - 11 months ago

Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%

Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands

Sep 25, 2024, 9:25 AM EDT - 1 year ago

Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands

Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins

Sep 23, 2024, 12:55 PM EDT - 1 year ago

Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins

Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits

Sep 23, 2024, 9:00 AM EDT - 1 year ago

Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits

Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion

Sep 19, 2024, 3:40 PM EDT - 1 year ago

Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion

Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments

Sep 18, 2024, 1:30 PM EDT - 1 year ago

Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

VRAX

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

VRAX

Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements

Aug 23, 2024, 9:35 AM EDT - 1 year ago

Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

Aug 21, 2024, 10:20 AM EDT - 1 year ago

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

VRAX

Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs.

Aug 20, 2024, 12:20 PM EDT - 1 year ago

Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs.

Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit

Aug 20, 2024, 9:00 AM EDT - 1 year ago

Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit

Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market

Aug 8, 2024, 1:00 PM EDT - 1 year ago

Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market

Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share

Aug 6, 2024, 9:00 AM EDT - 1 year ago

Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share

Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland

Jul 25, 2024, 2:45 PM EDT - 1 year ago

Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland

Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar

Jul 25, 2024, 11:40 AM EDT - 1 year ago

Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar

Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity

Jul 24, 2024, 10:55 AM EDT - 1 year ago

Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity

Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units

Jul 18, 2024, 3:45 PM EDT - 1 year ago

Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units

Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market

Jul 10, 2024, 3:45 PM EDT - 1 year ago

Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market

Luvmepup
Luvmepup Sep. 7 at 1:07 PM
$COSM Investors before Sept 29
0 · Reply
Luvmepup
Luvmepup Sep. 7 at 1:05 PM
$COSM Don't forget baggies, this has to be at or above $1 for ten straight business days BEFORE Nov. My prediction ... as soon as this crooked CEO gets the approval for a Reverse Split Sept 29, BOOM!
0 · Reply
Luvmepup
Luvmepup Sep. 7 at 12:30 PM
$COSM Just to be clear ... this scam will continue to get hammered this week!
0 · Reply
Kid_Shelleen
Kid_Shelleen Sep. 7 at 11:19 AM
$COSM COSM
0 · Reply
lightstorm
lightstorm Sep. 7 at 5:52 AM
$COSM Just to be clear, COSM has about 32M shares outstanding right now. The 1.5B number in the proxy refers only to authorized shares, which is the legal ceiling the company could issue in the future. That doesn’t mean they issue those shares and the float suddenly jumps to 1.5B . Issuing new shares would require separate offerings and board decisions, it’s not automatic. Outstanding shares remain what they are unless new shares are actually issued. This is a standard step for small caps to keep financing options open, not an automatic dilution event.
0 · Reply
lightstorm
lightstorm Sep. 7 at 5:32 AM
$COSM Worth keeping in mind — filing a proxy for reverse split authority is standard Nasdaq procedure whenever a stock is under $1 near a deadline. It doesn’t mean a split is automatic. In 2024, COSM regained compliance organically without touching the split authority because they pushed strong PRs and growth news. Greg still holds millions of shares himself, so his interests are aligned with ours. The 14A just gives the board a fallback option if all else fails — nothing unusual about that. What matters now is whether management executes the same playbook (PR cadence + catalysts) to get us back over $1 before November.
0 · Reply
WallStVisions
WallStVisions Sep. 7 at 1:01 AM
SKYQ is building something big: → Tokenizing energy assets → Expanding clean-tech operations → Bottomed chart, tiny cap → Major upside if volume steps in This one can go from sleeper to spotlight real quick… $MBOT $PEV $COSM $LEXX
0 · Reply
Luvmepup
Luvmepup Sep. 6 at 8:42 PM
$COSM You baggies do realize you are about to lose your asses this week? What made you think holding longer would cause pigs to start flying? This week will be a complete shit-show ... DO NOT DOUBT ME! This crooked CEO is hemorrhaging cash like nobody's business ... hence the new Offering. He also knows he will never be able to get back to $1 ... hence the Reverse Split that no doubt is coming right after the proxy vote in three weeks.
0 · Reply
Luvmepup
Luvmepup Sep. 6 at 6:56 PM
$COSM To think, poster BearTrapper used to deny what I was telling him and this board for years about how corrupt this company/CEO was/is. Now he realizes what a "dirty scam" this company is. Still no apology though.
0 · Reply
WallStVisions
WallStVisions Sep. 6 at 5:58 PM
SKYQ isn’t just undervalued it’s misunderstood. This is a blockchain + energy sleeper play with real revenue, a real platform, and no dilution. It’s not a matter of if this explodes it’s when. $1+ is right there…. $PEV $SNTI $COSM $VERB
0 · Reply
BearTrapperA57
BearTrapperA57 Sep. 6 at 5:06 PM
$COSM From 32 million shares outstanding to 1.5 BILLION, theres no way if this gets passed that this stock will stay listed as NASDAQ. Unbelievable
0 · Reply
BearTrapperA57
BearTrapperA57 Sep. 6 at 5:02 PM
$COSM Just got the email from Greg. He is proposing yet another reverse split, and more offering dilution like always. This company is such a dirty scam.
0 · Reply
Kid_Shelleen
Kid_Shelleen Sep. 6 at 4:32 PM
$COSM Saturday in the park...
0 · Reply
Luvmepup
Luvmepup Sep. 6 at 1:53 AM
$COSM Folks, this ship has sunk! Take what little you have left before the Recerse Split and treat your family (if they didn't leave you already) to a nice McDonald's dinner.
0 · Reply
Kid_Shelleen
Kid_Shelleen Sep. 6 at 1:49 AM
$COSM everybody knows that the dice are loaded. Leonard Cohen.
0 · Reply
Kid_Shelleen
Kid_Shelleen Sep. 6 at 1:46 AM
$COSM the chump blocked me cause it's a negative thing. Block the noise. Get rid of the leeches.
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 6 at 12:02 AM
🌙 EOD Recap ✅ $COSM 🗓️ Sep 5, 2025 (8pm ET) 💵 Our Entry: $0.6600 🎯 Target: $0.7765 (+17.65%)
0 · Reply
Kid_Shelleen
Kid_Shelleen Sep. 5 at 10:54 PM
$COSM I'll spend the whole weekend posting positive news if I have to. Let's start with this. https://finance.yahoo.com/news/cosmos-health-enters-u-market-150016883.html
0 · Reply
Kid_Shelleen
Kid_Shelleen Sep. 5 at 10:53 PM
$COSM clowns get back in the barrel. The Bullfight is over. Yer a mess.
0 · Reply
gio5528
gio5528 Sep. 5 at 8:26 PM
$COSM bounced off my line from a few years ago at .61. I think this will bounce back to about .83.
0 · Reply
Kid_Shelleen
Kid_Shelleen Sep. 5 at 8:10 PM
$COSM Nice. still winning under the curve. While averaging down from years ago.
0 · Reply
Luvmepup
Luvmepup Sep. 5 at 7:57 PM
$COSM So now poster BearTrapper is finally agreeing with me and saying what I've been telling you all for years. Be a man and post you were wrong and I was right this whole time and apologize!
0 · Reply